Artificial Olfactory Sensor for Diabetes Prediction via VOC Capture

The patent uses VOCs as an intermediary biomarker that indirectly reflects diabetes-related metabolic changes in the microbiome. Instead of directly measuring blood glucose or hemoglobin, the system detects volatile compounds produced by microbial metabolism, which serve as a mediator that is not affected by human physiological variations or medication interference.

The invention creates a surrogate measurement system that copies the metabolic information present in VOCs rather than directly measuring the primary diabetes indicators. The electronic nose captures a pattern of volatile compounds that replicate the metabolic state associated with diabetes risk, providing an alternative copy of the diagnostic information that avoids the limitations of direct blood testing.

The patent employs VOCs as a population-independent intermediary marker. Different microbial species produce characteristic volatile profiles that reflect their metabolic activity regardless of the host's physiological state. This intermediary approach allows the same detection system to work reliably across diverse populations including pregnant women, smokers, and anemic patients who cannot undergo A1C testing.

The electronic nose device provides a universal diagnostic tool that functions across all population groups. By detecting microbial VOCs rather than human blood parameters, the system achieves multi-functionality and broad applicability, serving as a universal screening method that adapts to different user groups without requiring population-specific calibration or alternative testing protocols.

The patent employs a disposable or low-cost sensor array that detects VOCs without requiring expensive laboratory infrastructure. The electronic nose uses relatively simple chemical sensors that can be manufactured at low cost, eliminating the need for expensive sequencing equipment, specialized facilities, and highly trained personnel required by current microbiome analysis methods.

The invention replaces complex mechanical and computational laboratory systems with a simpler chemical sensing approach. Instead of using sophisticated sequencing machinery, bioinformatics pipelines, and complex data analysis systems, the patent uses direct chemical detection of volatile compounds, substituting a simpler sensing mechanism for the complex mechanical and computational infrastructure of current microbiome assessment methods.

The patent enables preliminary detection of diabetes risk by identifying characteristic VOC patterns that precede clinical diabetes diagnosis. The system detects early microbial metabolic changes that occur before significant hyperglycemia develops, allowing preventative interventions to be initiated in the prediabetic stage when lifestyle changes are most effective.

The invention skips the intermediate stage of clinical diabetes diagnosis by directly detecting early microbial markers of diabetes risk. Rather than waiting for blood glucose levels to rise to diagnostic thresholds, the system rushes through the detection process by identifying VOC patterns that indicate impending diabetes, thereby capturing the prevention window before traditional methods would detect the condition.